GoHealth price target lowered to $10 from $20 at Noble Capital

Noble Capital analyst Patrick McCann lowered the firm’s price target on GoHealth (GOCO) to $10 from $20 and keeps an Outperform rating on the shares. Q3 results came in below expectations and management expects the current environment to last several quarters as carriers recalibrate benefit structures and cost models, notes the analyst, whose Q4 and 2026 forecasts are now “materially lower than our previous estimates.” However, the firm believes the long-term revenue and margin potential remain attractive once the Medicare Advantage market stabilizes, the analyst tells investors.